LabCorp Exclusively Launches Sera Prognostics’ PreTRM Test to Assess for Risk of Preterm Birth
May 23 2017 - 8:15AM
Business Wire
The PreTRM Test is the Only Validated Test That
Provides Early and Individualized Evaluation of Preterm Birth
Risk
LabCorp® (NYSE: LH) today announced the nationwide availability
of the PreTRM® test. Developed by Sera Prognostics, Inc., the
PreTRM test is the first of its kind validated blood test that
provides an early and individualized prediction of preterm birth
risk for pregnant women. LabCorp and Sera previously announced
their strategic collaboration for LabCorp to be the exclusive U.S.
distributor of Sera’s PreTRM test. LabCorp was also a lead investor
in Sera’s recently closed Series C financing round.
“As the exclusive U.S. laboratory to offer Sera’s PreTRM test,
LabCorp continues to build a leading position in women’s and
reproductive health diagnostics,” said Gary M. Huff, chief
executive officer of LabCorp Diagnostics. “We are excited about our
collaboration with Sera, and this innovative test is part of our
ongoing strategy to deliver world-class diagnostics that can
improve health and lives.”
The PreTRM test is performed on a standard blood specimen
collected during weeks 19 and 20 of pregnancy. The specimen must be
collected at one of LabCorp’s over 1,750 patient service
centers.
The test can help physicians provide better care by helping to
predict the risk of preterm birth, providing the opportunity to
intervene earlier to help extend the pregnancy towards full-term.
Preterm birth is the leading cause of infant mortality and
morbidity in the U.S. and worldwide. Approximately 400,000 of the
4,000,000 annual births in the U.S. are preterm, defined as prior
to week 37 of pregnancy, and up to 50 percent of women who delivery
prematurely do not have any identified risk factors for preterm
birth. According to the March of Dimes, the average cost of care
for a premature baby is ten times the average cost for a full-term
baby. Children born prematurely can require long-term or lifetime
care, with significant additional cost. Each additional week
towards full-term pregnancy can help to prevent mortality, improve
a variety of health outcomes, including respiratory and
neurodevelopmental outcomes, and eliminate or reduce the expense
and impact of caring for a preterm infant.
The PreTRM test was supported by the landmark Proteomic
Assessment of Preterm Risk study, which followed over 5,500
pregnant women, analyzed over 300 proteins in maternal blood and
identified a two-protein signature that was found to be highly
predictive of spontaneous preterm birth. The test is a significant
addition to LabCorp’s differentiated women’s healthcare and
reproductive genetics offerings. These include MaterniT®21, a
proprietary, clinically validated non-invasive prenatal test, and
the industry’s largest network of genetic counselors who can help
patients understand genetic test results. In addition, LabCorp
offers patient-focused services such as support to obtain insurance
pre-authorization before a test is performed and a personalized
estimate of the out-of-pocket cost of services before specimen
collection by LabCorp.
For more information about the PreTRM test, please visit
www.PreTRM.com and the PreTRM test YouTube Channel. You can also
join the conversation on Facebook and @PreTRM. For more information
about LabCorp’s comprehensive pregnancy services from preconception
through delivery, including the PreTRM test, please visit
www.labcorp.com/provider-services/programs/partners-pregnancy.
About the PreTRM Test
The PreTRM test is the first of its kind validated blood test
that provides an early and individual risk prediction for
spontaneous preterm birth in asymptomatic, singleton pregnancies.
The PreTRM test measures and analyzes proteins in the blood that
are highly predictive of preterm birth. The PreTRM test can help
physicians identify early in the pregnancy (as early as 19 weeks of
gestation) which women are at increased risk for premature
delivery, enabling more informed clinical decisions based on each
woman’s individual risk. The PreTRM test enables researchers to
better understand the causes of preterm birth and to develop new
therapies to improve newborn health. The PreTRM test is ordered by
a medical professional.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostic solutions,
brings innovative medicines to patients faster and uses technology
to improve the delivery of care. LabCorp reported net revenues of
nearly $9.5 billion for 2016 through the contributions of 52,000
employees in approximately 60 countries. To learn more about
LabCorp, visit www.labcorp.com, and to learn more about Covance
Drug Development, visit www.covance.com.
This press release contains forward-looking statements including
with respect to estimated 2017 guidance and the impact of various
factors on operating and financial results. Each of the
forward-looking statements is subject to change based on various
important factors, including without limitation, competitive
actions in the marketplace, and adverse actions of governmental and
other third-party payers. Actual results could differ materially
from those suggested by these forward-looking statements. The
Company has no obligation to provide any updates to these
forward-looking statements even if its expectations change. Further
information on potential factors that could affect operating and
financial results is included in the Company’s Form 10-K for the
year ended December 31, 2016, and subsequent Forms 10-Q, including
in each case under the heading risk factors, and in the Company’s
other filings with the SEC. The information in this press release
should be read in conjunction with a review of the Company’s
filings with the SEC including the information in the Company’s
Form 10-K for the year ended December 31, 2016, and subsequent
Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170523005640/en/
LabCorpMedia Relations:Pattie Kushner,
336-436-8263Media@labcorp.comorInvestor Relations:Scott Frommer,
336-436-5076Investor@labcorp.com
Labcorp (NYSE:LH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Labcorp (NYSE:LH)
Historical Stock Chart
From Sep 2023 to Sep 2024